NCT06616766View on ClinicalTrials.gov

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

March 15, 2028

Study Completion Date

July 29, 2028

Conditions
NSCLC (Non-small Cell Lung Cancer)Solid Tumor
Interventions
DRUG

YH42946

YH42946

Trial Locations (8)

13620

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

16247

NOT_YET_RECRUITING

The Catholic Univ. of Korea St. Vincent's Hospital, Suwon

22031

RECRUITING

Next Oncology Virginia, Fairfax

28644

RECRUITING

Chungbuk National University Hospital, Cheongju-si

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Severance Hospital, Yonsei University, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

Unknown

RECRUITING

Asan Medical Center, University of Ulsan, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY